Clinical, Humanistic, and Economic Value of ‘Good ON-Time’ in Advanced Parkinson’s Disease: A Multinational Real-World Study
Authors:
- Joohi Jimenez-ShahedJJJoohi Jimenez-Shahed
- Irene A. MalatyIMIrene A. Malaty
- Jean-Philippe AzulayJAJean-Philippe Azulay
- Ashwini ParabAPAshwini Parab
- Connie H. YanCYConnie H. Yan
- Prasanna L. KandukuriPKPrasanna L. Kandukuri
- Pavnit KukrejaPKPavnit Kukreja
- Jorge ZamudioJZJorge Zamudio
- Alexander GillespieAGAlexander Gillespie
- Angelo AntoniniAngelo Antonini
Open Access
- 2 June 2025
- journal article
- research article
- Published by Springer Nature in Neurology and Therapy
- Vol. 14 (4) , 1475-1493
Abstract
Introduction In advanced Parkinson's disease (aPD), ‘ON-time’ indicates periods of better symptom control, with ‘good ON-time (GOT)’ indicating control without troublesome dyskinesia. Despite its importance, the impact of increased ‘GOT’ on aPD outcomes is understudied. This study aims to evaluate the clinical, humanistic, and economic value of incremental hourly increases in ‘GOT’ for people with aPD. Methods The study analyzed data from people with aPD across seven countries, using the Adelphi Parkinson's Disease Specific Program survey (2017–2020). ‘GOT’ (calculated from self-reported ON/OFF-time and the proportion of troublesome dyskinesia time) was normalized to a 16-h day. Outcomes included symptom control, medication use, falls, activities of daily living (ADLs), quality of life (QoL), and healthcare resource utilization (HRU). Regression models evaluated relationships between incremental ‘GOT’ hours and outcomes. Results Of 802 patients (mean [standard deviation; SD] age, 76.1 [8.9] years; male, 60.3%) included in the analysis, mean (SD) ‘GOT’ was 13.1 (2.7) hours/day. Hourly increases in ‘GOT’ were associated with lower likelihood of reporting uncontrolled motor (odds ratio [OR] 0.79; 95% confidence interval (CI) [0.62, 1.01]) and non-motor symptoms (OR 0.88; 95% CI [0.80, 0.96]), taking ≥ 2 PD medication classes (OR 0.91; 95% CI [0.86, 0.97]) and lower fall risk (incidence rate ratio 0.91; 95% CI [0.87, 0.95]). Hourly increases in ‘GOT’ were significantly associated with reduced humanistic burden (greater ADL independence, OR 1.19; 95% CI [1.04 1.37]) and improved QoL (for Parkinson’s Disease Questionnaire [PDQ]-39: coefficient − 1.49; 95% CI [− 2.46, − 0.52]) and with reduced economic burden, with annual total HRU cost-savings of $8602.24 (95% CI − $12,192.70 to $5011.77). Conclusions In this multi-country, real-world study of people with aPD, hourly increases in ‘GOT’ were associated with improved clinical outcomes, greater humanistic value, and reduced economic burden. Interventions that maximize improvement of ‘GOT’ should be considered for people with aPD adequately controlled on current therapy.Keywords
Funding Information
- AbbVie
This publication has 35 references indexed in Scilit:
- Economic Burden of Parkinson’s Disease: A Multinational, Real-World, Cost-of-Illness StudyDrugs - Real World Outcomes, 2024
- Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 StudyNeurology and Therapy, 2023
- Impact of advanced Parkinson’s disease on caregivers: an international real-world studyJournal of Neurology, 2023
- Patterns of Daily Motor-Symptom Control with Carbidopa/Levodopa Enteral Suspension Versus Oral Carbidopa/Levodopa Therapy in Advanced Parkinson’s Disease: Clinical Trial Post Hoc AnalysesNeurology and Therapy, 2022
- Psychometric Properties of Clinical Indicators for Identification and Management of Advanced Parkinson’s Disease: Real-World Evidence From G7 CountriesNeurology and Therapy, 2022
- Burden of Parkinson's Disease by Severity: Health Care Costs in the U.S. Medicare PopulationMovement Disorders, 2020
- Dyskinesia Matters: But Not as Much as It Used toMovement Disorders, 2020
- Bilateral Deep Brain Stimulation vs Best Medical Therapy for Patients With Advanced Parkinson DiseaseA Randomized Controlled TrialJAMA, 2009
- Parkinson's disease home diary: Further validation and implications for clinical trialsMovement Disorders, 2004
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987